|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The dual use of basal insulin plus GLP-1 RA is non-inferior compared with basal insulin plus a single injection of prandial insulin at the largest meal and compared with twice daily-dosed premixed insulins; and this combination is associated with weight loss and less hypoglycemia.
|
29796245 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
When all GLP-1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk.
|
27981757 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
|
29272081 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials.
|
29334278 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A short-acting GLP-1RA plus basal insulin is an alternative to premixed insulin, resulting in better efficacy and a lower risk of hypoglycemia and weight gain.
|
30859500 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide an alternative to prandial insulin, with the benefits of fewer daily injections, and a lower risk of hypoglycemia and weight gain.
|
30610613 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are also effective in terms of glycemic control and associated with weight loss and low risk of hypoglycemia.
|
29636825 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nausea and vomiting rates as well as numbers of documented symptomatic hypoglycemia events per patient-year were generally low but greater with iGlarLixi versus continued GLP-1 RA therapy.
|
31530665 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observed benefits in GV and hypoglycemia may contribute to the cardiovascular outcome reduction seen with GLP-1 RA therapy and should be investigated further.
|
27913575 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk.
|
29364586 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.
|
27975209 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia.
|
31801807 |
2020 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BI in combination with GLP-1 RAs appears to be an effective intensification strategy, further reducing A1C levels and hypoglycemia frequency compared to increasing BI doses.
|
28816532 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss and importantly the observed benefits in cardiovascular disease reduction.
|
31686781 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia.
|
28102093 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of hypoglycemia was increased with TZD or GLP-1RA.
|
29511288 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of hypoglycemia with GLP-1RAs is minimal; however, GLP-1RAs are associated with gastrointestinal adverse events and raise concerns regarding pancreatitis.
|
28526416 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
|
31176298 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
|
31275246 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results for third-line agents added to metformin and TZDs were comparable, showing similar HbA1c reduction and risk of hypoglycaemia between SGLT-2 inhibitors and GLP-1RAs, and a slightly greater reduction in body weight with SGLT-2 inhibitors vs GLP-1RAs.
|
29205774 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs may be considered in combination with other glucose-lowering medications because of their ability to lower glucose in a glucose-dependent manner, lowering their risk for hypoglycemia, while improving some cardiorenal risk factors.
|
31318152 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1 RA intensifiers had equivalent glycemic control to RAI or other injectables, with a nonsignificantly lower risk of hypoglycemia and reduction in body weight.
|
29975575 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are drugs used in type 2 diabetes that have a low risk of hypoglycemia and have been shown to exert neuroprotective effects.
|
31518433 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expert opinion: IDegLira provides superior glycaemic control and mitigates the primary adverse effects associated with insulin therapy (weight gain and hypoglycaemia) and GLP-1RAs (gastrointestinal side effects) with no indication of additive effects.
|
28150516 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1RAs are generally well tolerated, with gastrointestinal and injection-site reactions being the most troublesome drug-related adverse events, and are associated with a very low intrinsic risk of hypoglycaemia.
|
31317516 |
2019 |